HER2 is Rarely Expressed in Endometrial Carcinoma in Sudanese Population
DOI:
https://doi.org/10.56294/saludcyt20252025Keywords:
Endometrial Carcinoma, HER2, ImmunohistochemistryAbstract
Background
Endometrial cancer (EC) is the most common gynecologic cancer in high-income countries, and its incidence is increasing in low-and middle-income nations. Although differentiating between high-grade and low-grade tumors is mandatory for the survival of the patients, histomorphology alone has limited reproducibility owing to the overlapping of the morphologic features by routine H&E stain. Human Epidermal Growth Factor Receptor 2 (HER2) expression has been observed in various cancers with a potential role in prognosis and targeted therapy for EC. The study aims to explore the HER2 expression pattern and its potential role as a natural history predictor and target therapy in EC among Sudanese women.
Methods
A cohort of fifty-four Sudanese female patients diagnosed with endometrial cancer (EC) was evaluated for HER2 expression through immunohistochemistry using the Hercep Test (Dako, Glostrup, Denmark) from January 2019 to October 2021.
Results
The results showed that 92.59% of the cases were negative (0 or 1+), 5.56% were equivocal (2+), and only 1.85% were positive (3+). A statistically significant correlation was identified between HER2 expression and histological subtypes (P value = 0.01). However, the association between HER2 expression and tumor grade was insignificant (P value = 0.06). Additionally, no significant correlation was found between HER2 expression and lymphovascular invasion within the tumor (P value = 0.49).
Conclusion
The overexpression of HER2 is not prevalent among Sudanese patients diagnosed with endometrial carcinoma.
Keywords: Endometrial carcinoma, HER2, Immunohistochemistry.
References
1. Elamin A, Ibrahim ME, Abuidris D, Mohamed KEH, Mohammed SI. Part I: cancer in Sudan—burden,
distribution, and trends breast, gynecological, and prostate cancers. Cancer Med. 2015 Mar;4(3):447–56.
2. Mazidimoradi A, Momenimovahed Z, Khalajinia Z, Allahqoli L, Salehiniya H, Alkatout I. The global
incidence, mortality, and burden of uterine cancer in 2019 and correlation with SDI, tobacco, dietary risks, and
metabolic risk factors: An ecological study. Health Sci Rep. 2024 Jan 25;7(1):e1835.
https://doi.org/10.56294/saludcyt20252025
ISSN: 2796-9711
Salud, Ciencia y Tecnología. 2025; 5:2025 8
3. Raffone A, Travaglino A, Raimondo D, Maletta M, De Vivo V, Visiello U, et al. Uterine carcinosarcoma vs
endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival. Int J Gynaecol
Obstet. 2022 Sept;158(3):520–7.
4. Gao S, Wang J, Li Z, Wang T, Wang J. Global Trends in Incidence and Mortality Rates of Endometrial
Cancer Among Individuals Aged 55 years and Above From 1990 to 2021: An Analysis of the Global Burden of
Disease. Int J Womens Health. 2025;17:651–62.
5. Sun Z, Shi Y, Shen Y, Cao L, Zhang W, Guan X. Analysis of different HER-2 mutations in breast cancer
progression and drug resistance. J Cell Mol Med. 2015;19(12):2691–701.
6. English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for
gynecologic malignancies. Mol Diagn Ther. 2013 Apr;17(2):85–99.
7. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and
Therapeutic Implications. Mol Biol Int. 2014;2014:852748.
8. Thibault C, Khodari W, Lequoy M, Gligorov J, Belkacémi Y. HER2 status for prognosis and prediction of
treatment efficacy in adenocarcinomas: a review. Crit Rev Oncol Hematol. 2013 Oct;88(1):123–33.
9. Palladini A, Nicoletti G, Lamolinara A, Dall’Ora M, Balboni T, Ianzano ML, et al. HER2 isoforms co
expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.
Oncotarget. 2017 Aug 15;8(33):54444–58.
10. Watkins JC, Downing MJ, Crous-Bou M, Busch EL, Chen M, De Vivo I, et al. Endometrial Tumor
Classification by Histomorphology and Biomarkers in the Nurses’ Health Study. J Cancer Epidemiol. 2021 Mar
12;2021:8884364.
11. Huang CY, Chen CA, Chen YL, Chiang CJ, Hsu TH, Lin MC, et al. Nationwide Surveillance in Uterine
Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in Taiwan.
PLOS ONE. 2012 Dec 10;7(12):e51372.
12. Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, et al. HER2-low expression in patients
with advanced or metastatic solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2023 Nov;34(11):1035–46.
13. Mohapatra K, Shivalingaiah S devi C. Immunohistochemical Expression of ER, PR and HER2/neu in
Endometrial Carcinoma. Indian J Gynecol Oncol. 2019 June 6;17(3):54.
14. Suthipintawong C, Wejaranayang C, Vipupinyo C. Prognostic significance of ER, PR, Ki67, c-erbB-2, and
p53 in endometrial carcinoma. J Med Assoc Thail Chotmaihet Thangphaet. 2008 Dec;91(12):1779–84.
15. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, et
al. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer
Prev APJCP. 2010;11(1):215–20.
16. Lapińska-Szumczyk S, Supernat A, Majewska H, Gulczyński J, Luczak A, Biernat W, et al. HER2-positive
endometrial cancer subtype carries poor prognosis. Clin Transl Sci. 2014 Dec;7(6):482–8.
17. Peiró G, Mayr D, Hillemanns P, Löhrs U, Diebold J. Analysis of HER-2/neu amplification in endometrial
carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu,
p53 and Ki-67 protein expression, and outcome. Mod Pathol Off J U S Can Acad Pathol Inc. 2004 Mar;17(3):227–87.
18. Saeed M, Ahmad A, Hassawi B. Overexpression of Her-2/neu oncogene in 51 cases of endometrial
carcinoma. Jordan Med J [Internet]. 2013 Sept 23 [cited 2025 May 29];47(3). Available from: https://archives.
ju.edu.jo/index.php/jmj/article/view/4974
19. Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, et al. Human Epidermal Growth
Factor 2 (HER2) in Early Stage Uterine Serous Carcinoma: A Multi-Institutional Cohort Study. Gynecol Oncol.
2020 Oct;159(1):17–22.
https://doi.org/10.56294/saludcyt20252025
ISSN: 2796-9711
9
Mohager SO, et al
20. Shao Y, Xu R, Shi H, Ye L, Wang H, Lu B. Human epidermal growth factor 2 (HER2) amplification in
uterine serous carcinoma: an analysis of prognosis and immune microenvironment. Virchows Arch. 2025 Apr
1;486(4):707–19.
21. Sukov WR, Zhou J, Geiersbach KB, Keeney GL, Carter JM, Schoolmeester JK. Frequency of HER2 protein
overexpression and HER2 gene amplification in endometrial clear cell carcinoma. Hum Pathol. 2023 July;137:94
101.
22. Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF, et al. An exploratory analysis
of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group
study. Gynecol Oncol. 2008 Jan;108(1):3–9.
23. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent
prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
J Clin Oncol Off J Am Soc Clin Oncol. 2006 May 20;24(15):2376–85.
24. Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, et al. Determination of
HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and
f
luorescence in situ hybridization. Gynecol Oncol. 2005 July;98(1):24–30.
25. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary
serous cancers and its possible therapeutic implications. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc.
2006;16(5):1897–902.
26. Abada E, Kim S, Jang H, Kheil M, Singh K, Bandyopadhyay S, et al. Human epidermal growth factor
receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic
characteristics and future directions. Gynecol Oncol. 2024 June;185:25–32.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Samah Mohager, Prof. Imad M. Fadl-Elmula, Dr. Mehad Alfatih, Dr. Asma Abd Elwhab , Dr. Ruba Ahmed, Dr. Omayma Mohamed Osman, Dr. Nadia El-Dawi (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
